Loading quotes...
Forecast
| Buy |
0 |
| Hold |
0 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2025 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -159.1 | - |
| EBITDA | 0 | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €5.5k |
Number of shares | 41.71k |
52-week high/low | €0.17 - €0.00 |
| Dividends | No |
Beta | 0.21 |
P/E ratio | 18.43 |
PEG ratio | 0.03 |
P/B ratio | 1.28 |
P/S ratio | 60.15 |
Company profile
Orphazyme A/S does not have significant operations. Previously, the company was engaged in the development of therapies for the treatment of neurodegenerative rare diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.
| Name | Orphazyme Aktie |
| CEO | Jakob Færch Bendtsen |
| Headquarters | Copenhagen,
Denmark |
| Website | |
| IPO | 16/07/2019 |
| Employees | 1 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Copenhagen | ORPHA.CO |
Frankfurt | 1TB0.F |
London | 0CUM.L |
München | 1TB0.MU |
Düsseldorf | 1TB0.DU |
